Press Release

Intersect ENT Agrees to Sell to Medtronic for More Than $1 Billion

August 17, 2021

Palo Alto – August 17, 2021 – Cooley advised Intersect ENT, a global ear, nose and throat medical technology leader dedicated to transforming patient care, on its agreement to sell to medical technology company Medtronic in an all-cash transaction valued at $1.1 billion. Lawyers Steve Tonsfeldt, Matthew Hemington, Kevin Cooper and Matthew Silverman led the Cooley team advising Intersect ENT.

The acquisition of Intersect ENT expands Medtronic’s portfolio of products used during ear, nose and throat procedures. The complementary product lines and customer base will further Medtronic’s efforts to have a positive impact for patients who suffer from chronic rhinosinusitis (CRS). By combining Intersect ENT’s sinus implants with Medtronic’s navigation systems, powered instruments and existing tissue health products, Medtronic intends to offer a broader suite of solutions to assist surgeons treating CRS patients.

“This is an exciting day for patients suffering from CRS,” Thomas West, president and chief executive officer of Intersect ENT, said in a news release. “After years of pioneering technology to help patients heal following sinus surgery, we welcome the integration of Intersect ENT’s portfolio into Medtronic. We are looking forward to the global impact we can make as part of Medtronic, bringing these essential products to more patients than ever before.”

Intersect ENT is a global ENT medical technology leader dedicated to transforming patient care. The company’s steroid-releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. Intersect ENT is continuing to expand its portfolio of products based on its unique, localized steroid-releasing technology, and is committed to broadening patient access to less invasive and more cost-effective care.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,300 lawyers across 17 offices in the United States, Asia and Europe.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.